TP53 and Epstein-Barr virus infection: Among diffuse-mixed tumors (n = 32), E-cadherin aberrant expression was reported in 17/32 (53.1%), followed by p53 aberrant expression in 5/32 (15.6%), p53 normal expression in 5/32 (15.6%), EBV infection in 3/32 (9.4%), and MSI phenotype in 2/32 (6.2%).